Craig-Hallum analyst William Bonello maintained a Buy rating on CareDx (CDNA – Research Report) today. The company’s shares closed last Friday at $9.72.
Bonello covers the Healthcare sector, focusing on stocks such as Cerus, CareDx, and Natera. According to TipRanks, Bonello has an average return of 39.0% and a 68.00% success rate on recommended stocks.
CareDx has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.
The company has a one-year high of $12.93 and a one-year low of $4.80. Currently, CareDx has an average volume of 813.1K.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CDNA in relation to earlier this year. Earlier this month, Peter Maag, a Director at CDNA bought 13,281.00 shares for a total of $69,990.87.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CareDx (CDNA) Company Description:
CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
